Erasca, Inc. Contracts & Agreements
34 Contracts & Agreements
- Business Finance (6 contracts)
- Business Operations (2)
- Human Resources (15)
- Intellectual Property (5)
- Mergers & Acquisitions (1)
- Real Estate (2)
- Uncategorized (3)
- Erasca, Inc. Non-Employee Director Compensation Program (Filed With SEC on March 27, 2024)
- First Amendment to Exclusive License Agreement, dated August 7, 2023, by and between Novartis Pharma AG and the Registrant (Filed With SEC on November 9, 2023)
- Amended and Restated Employment Letter Agreement, dated April 10, 2023, between Shannon R. Morris, M.D., Ph.D. and Erasca, Inc (Filed With SEC on August 10, 2023)
- Underwriting Agreement, dated December 9, 2022, by and among Erasca, Inc. and J.P. Morgan Securities LLC and Goldman Sachs & Co. LLC, as representatives of the several... (Filed With SEC on December 9, 2022)
- Description of Securities (Filed With SEC on March 24, 2022)
- Amended and Restated Employment Letter Agreement, dated July 9, 2021, by and between Wei Lin, M.D. and the Registrant (Filed With SEC on July 12, 2021)
- Form of Underwriting Agreement (Filed With SEC on July 12, 2021)
- Erasca, Inc. 2021 Incentive Award Plan and form of stock option agreement and form of restricted stock unit agreement thereunder (Filed With SEC on July 12, 2021)
- Erasca, Inc. 2021 Employee Stock Purchase Plan (Filed With SEC on July 12, 2021)
- Erasca, Inc. Severance and Change in Control Severance Plan and Summary Plan Description (Filed With SEC on July 12, 2021)
- Non-Employee Director Compensation Program (Filed With SEC on July 12, 2021)
- Amended and Restated Employment Letter Agreement, dated July 9, 2021, by and between Jonathan E. Lim, M.D. and the Registrant (Filed With SEC on July 12, 2021)
- Amended and Restated Employment Letter Agreement, dated July 9, 2021, by and between David M. Chacko, M.D. and the Registrant (Filed With SEC on July 12, 2021)
- Amended and Restated Employment Letter Agreement, dated July 9, 2021, by and between Ebun S. Garner and the Registrant (Filed With SEC on July 12, 2021)
- Form of Indemnification Agreement for Directors and Officers (Filed With SEC on July 12, 2021)
- Amended and Restated License Agreement, dated November 23, 2020, by and among the Registrants wholly-owned subsidiaries, ASN Product Development, Inc. and Asana BioSciences, LLC (Filed With SEC on June 25, 2021)
- Asset Purchase Agreement, dated March 12, 2021, by and between Emerge Life Sciences, PTE, LTD. and the Registrant (Filed With SEC on June 25, 2021)
- Employment Letter Agreement, dated March 27, 2021, by and between Ebun S. Garner and the Registrant (Filed With SEC on June 25, 2021)
- Amended and Restated Stockholders Agreement, dated April 15, 2020, by and among the Registrant and certain of its stockholders (Filed With SEC on June 25, 2021)
- Erasca, Inc. 2018 Equity Incentive Plan, as amended, including form of stock option agreement thereunder (Filed With SEC on June 25, 2021)
- Employment Letter Agreement, dated February 27, 2020, by and between Jonathan E. Lim, M.D. and the Registrant (Filed With SEC on June 25, 2021)
- Employment Letter Agreement, dated February 5, 2020, by and between David M. Chacko, M.D. and the Registrant (Filed With SEC on June 25, 2021)
- Release Agreement, dated December 15, 2020, by and between Gary Yeung and the Registrant (Filed With SEC on June 25, 2021)
- Employment Letter Agreement, dated August 18, 2020, by and between Michael D. Varney, Ph.D. and the Registrant (Filed With SEC on June 25, 2021)
- Scientific Advisory Board Agreement, dated August 15, 2020, by and between Michael D. Varney, Ph.D. and the Registrant (Filed With SEC on June 25, 2021)
- Employment Letter Agreement, dated November 5, 2020, by and between Wei Lin, M.D. and the Registrant (Filed With SEC on June 25, 2021)
- Specimen stock certificate evidencing the shares of common stock (Filed With SEC on June 25, 2021)
- Lease Agreement, dated September 29, 2020 by and between ARE-SD Region No. 23, LLC and the Registrant, as amended (Filed With SEC on June 25, 2021)
- Lease, dated July 27, 2018, by and between BMR-Road to the Cure LP and the Registrant, as amended (Filed With SEC on June 25, 2021)
- Exclusive License Agreement, dated December 21, 2018, by and between The Regents of the University of California and the Registrant, as amended (Filed With SEC on June 25, 2021)
- License Agreement, dated February 18, 2020, by and between NiKang Therapeutics, Inc. and the Registrant (Filed With SEC on June 25, 2021)
- Exclusive License Agreement, dated March 12, 2020, by and between Katmai Pharmaceuticals, Inc. and the Registrant (Filed With SEC on June 25, 2021)
- Licence Agreement, dated April 16, 2020, by and between LifeArc and the Registrant (Filed With SEC on June 25, 2021)
- Agreement and Plan of Merger, dated November 23, 2020, by and among the Registrant and its wholly-owned subsidiaries, ASN Product Development, Inc. and Asana BioSciences, LLC (Filed With SEC on June 25, 2021)